- Home
- ENGN vs ZNTL Comparison
ENGN vs ZNTL Comparison
Compare ENGN & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENGN
- ZNTL
- Stock Information
- Founded
- ENGN 1999
- ZNTL 2014
- Country
- ENGN Canada
- ZNTL United States
- Employees
- ENGN N/A
- ZNTL N/A
- Industry
- ENGN
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- ENGN
- ZNTL Health Care
- Exchange
- ENGN Nasdaq
- ZNTL Nasdaq
- Market Cap
- ENGN 293.1M
- ZNTL 273.1M
- IPO Year
- ENGN N/A
- ZNTL 2020
- Fundamental
- Price
- ENGN $7.68
- ZNTL $3.23
- Analyst Decision
- ENGN Strong Buy
- ZNTL Buy
- Analyst Count
- ENGN 7
- ZNTL 8
- Target Price
- ENGN $31.43
- ZNTL $10.50
- AVG Volume (30 Days)
- ENGN 69.9K
- ZNTL 1.6M
- Earning Date
- ENGN 09-10-2024
- ZNTL 11-12-2024
- Dividend Yield
- ENGN N/A
- ZNTL N/A
- EPS Growth
- ENGN N/A
- ZNTL N/A
- EPS
- ENGN N/A
- ZNTL N/A
- Revenue
- ENGN N/A
- ZNTL $40,560,000.00
- Revenue This Year
- ENGN N/A
- ZNTL N/A
- Revenue Next Year
- ENGN N/A
- ZNTL N/A
- P/E Ratio
- ENGN N/A
- ZNTL N/A
- Revenue Growth
- ENGN N/A
- ZNTL N/A
- 52 Week Low
- ENGN $4.42
- ZNTL $2.66
- 52 Week High
- ENGN $18.40
- ZNTL $18.07
- Technical
- Relative Strength Index (RSI)
- ENGN 44.37
- ZNTL 46.44
- Support Level
- ENGN $7.30
- ZNTL $2.90
- Resistance Level
- ENGN $7.97
- ZNTL $4.44
- Average True Range (ATR)
- ENGN 0.54
- ZNTL 0.37
- MACD
- ENGN -0.14
- ZNTL -0.06
- Stochastic Oscillator
- ENGN 21.60
- ZNTL 21.43
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.